Treating acute exacerbations of chronic bronchitis and community-acquired pneumonia: How effective are respiratory fluoroquinolones?

Canadian Family Physician

Volumn 52, Issue 10, 2006, Pages 1236-1242

  Balter, M ^a   Weiss, K ^b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM DERIVATIVE; BETA LACTAMASE INHIBITOR; CEFPROZIL; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN; CLARITHROMYCIN; CLAVULANIC ACID; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; PENICILLIN G; QUINOLONE DERIVATIVE; STEROID; TELITHROMYCIN; TETRACYCLINE; TROVAFLOXACIN;

ANTIBACTERIAL ACTIVITY; CHRONIC BRONCHITIS; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; CONTROLLED CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG USE; EVIDENCE BASED MEDICINE; GENERAL PRACTITIONER; HAEMOPHILUS INFLUENZAE TYPE A; HUMAN; MONOTHERAPY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ACUTE DISEASE; ANTI-BACTERIAL AGENTS; BRONCHITIS, CHRONIC; COMMUNITY-ACQUIRED INFECTIONS; COST-BENEFIT ANALYSIS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FLUOROQUINOLONES; HUMANS; PNEUMONIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS;

EID: 33845689355     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Balter MS, La Forge J, Low DE, Mandell L, Grossman RF; the Canadian Bronchitis Working Group on behalf of the Canadian Thoracic Society and the Canadian Infectious Diseases Society. Canadian guidelines for the management of acute exacerbations of chronic bronchitis. Can Respir J 2003;10:248-58.
2. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH; the Canadian Community-Acquired Pneumonia Working Group. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 2000;31:383-421.
3. Mandell L, Bartlett JG, Dowell SF, File TM, Musher DM, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003;37:1405-33.
4. Lode H, Garau J. Improving care for patients with respiratory tract infections. J Chemother 2002;14(Suppl 2):22-8.
5. Wilson R, Kubin R, Ballin I, Depperman KM, Bassaris HP, Leophonte P, et al. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1999;44:501-13.
6. Chodosh S, DeAbate CA, Haverstock D, Aneiro L, Church D. Short course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Respir Med 2000;94:18-27.
7. Schaberg T, Ballin I, Huchon G, Bassaris H, Hampel B, Reimnitz P. A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbations of chronic bronchitis. J Int Med Res 2001;29:314-28.
8. DeAbate CA, Mathew CP, Warner JH, Heyd A, Church D. The safety and efficacy of short course (5-day) moxifloxacin versus azithromycin in the treatment of patients with acute exacerbations of chronic bronchitis. Respir Med 2000;94:1029-37.
9. Wilson R, Allegra L, Huchon G, Izquierdo JL, Jones P, Schaberg T, et al; the MOSAIC Study Group. Short and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 2004;125:953-64.
10. Grassi C, Casali L, Mannelli S, Curti E, Tellarini M, Lazzaro C, et al; SMART Study Group. Efficacy and safety of short course (5-day) moxifloxacin vs 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis (AECB). J Chemother 2002;14:597-608.
11. Gotfried MH, DeAbate CA, Fogarty C, Mathew CP, Sokol W. Comparison of 5-day, short-course gatifloxacin therapy with 7-day gatifloxacin therapy and 10-day clarithromycin therapy for acute exacerbations of chronic bronchitis. Clin Ther 2001;23:97-107.
12. DeAbate CA, McIvor RA, McElvaine P, Skuba K, Pierce PF. Gatifloxacin vs cefuroxime axetil in patients with acute exacerbations of chronic bronchitis. J Respir Dis 1999;20(Suppl 11):S23-S29.
13. Shah PM, Maesen FPV, Dolmann A, Vetter N, Fiss E, Wesch R. Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbations of chronic bronchitis: results of a randomized, double-blind study. J Antimicrob Chemother 1999;43:529-39.
14. DeAbate CA, Russell M, McElvaine P, Faris H, Upchurch J, Fowler CL. Safety and efficacy of oral levofloxacin versus cefuroxime axetil in acute bacterial exacerbation of chronic bronchitis. Respir Care 1997;42:206-13.
15. Ball P, Wilson R, Mandell L, Brown J, Henkel T; the 069 Clinical Study Group. Efficacy of gemifloxacin in acute exacerbations of chronic bronchitis: a randomised, double-blind comparison with trovafloxacin. J Chemother 2001;13:288-98.
16. Wilson R, Schentag JJ, Ball P, Mandell L, for the 068 Study Group. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin Ther 2002;24:639-52.
17. Wilson R, Ball P, Mandell L, Adelglass J, Baird I, Schentag J; the 068 Clinical Study Group. Efficacy of once-daily gemifloxacin for 5 days compared with twice-daily clarithromycin for 7 days in the treatment of AECB. J Antimicrob Chemother 2001;47(Suppl 1):46.
18. Wilson R, Langan C, Ball P, Bateman K, Pypstra R; the Gemifloxacin 207 Clinical Study Group. Oral gemifloxacin once daily for 5 days compared with sequential therapy with iv ceftriaxone/oral cefuroxime (maximum of 10 days) in the treatment of hospitalized patients with acute exacerbations of chronic bronchitis. Respir Med 2003;97:242-9.
19. Torres A, Muir JF, Corris P, Kubin R, Duprat-Lomon I, Sagnier PP, et al. Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia. Eur Respir J 2003;21:135-43.
20. Welte T, Petermann W, Schurmann D, Bauer TT, Reimnitz P; MOXIRAPID Study Group. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy. Clin Infect Dis 2005;41(12):1697-705. Epub 2005 Nov 10.
21. Finch R, Schurmann D, Collins O, Kubin R, McGivern J, Bobbaers H, et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 2002;46(6):1746-54.
22. Fogarty C, Dowell ME, Ellison WT, Vrooman PS, White BJ, Mayer H. Treating community-acquired pneumonia in hospitalized patients: gatifloxacin vs ceftriaxone/clarithromycin. J Respir Dis 1999;20(Suppl 11):S60-S69.
23. Ramirez JA, Nguyen TH, Tellier G, Coppola G, Bettis RB, Dolmann A, et al. Treating community-acquired pneumonia with once-daily gatifloxacin vs twice-daily clarithromycin. J Respir Dis 1999;20(Suppl 11):S40-S48.
24. Sullivan JG, McElroy AD, Honsinger RW, McAdoo M, Harrison BJ, Plouffe JF, et al. Treating community-acquired pneumonia with once-daily gatifloxacin vs once-daily levofloxacin. J Respir Dis 1999;20(Suppl 11):S49-S59.
25. Marrie T, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. JAMA 2000;283:749-55.
26. Frank E, Liu J, Kinasewitz G, Moran GJ, Oross MP, Olson WH, et al. A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. Clin Ther 2002;24(8):1292-308.
27. Fogarty CM, Bettis RB, Griffin TJ, Keyserling CH, Nemeth MA, Tack KJ. Comparison of a 5 day regimen of cefdinar with a 10 day regimen of cefprozil for treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 2000;45:851-8.
28. Langan C, Zuck P, Vogel F, McIvor A, Pierzchala W, Smakal M, et al. Randomized, double-blind study of short course (5 day) grepafloxacin versus 10 day clarithromycin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother 1999;44:515-23.
29. Jones M, Karlowsky JA, Blosser-Middleton R, Critchley IA, Karginova E, Thornsberry C, et al. Longitudinal assessment of antipneumococcal susceptibility in the United States. Antimicrob Agents Chemother 2002;46:2651-5.
30. Low DE, de Azavedo J, Weiss K, Mazzulli T, Kuhn M, Church D, et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000. Antimicrob Agents Chemother 2002;46(5):1295-301.
31. Zhanel GG, Palatnick L, Nichol KA, Bellyou T, Low DE, Hoban DJ. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997-2002. Antimicrob Agents Chemother 2003;47:1867-74.
32. Weiss K, Restieri C, Jubinville N, Low DE; the EQUERE Project. Streptococcus pneumoniae resistance levels to beta-lactams, macrolides, fluoroquinolones and ketolides in Quebec, Canada in 2003: the importance of age [poster presentation at 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy]. 2003 Sep 14-17; Chicago, Ill. Abstr Intersci Conf Antimicrob Agents Chemother 2003;43:abstract no. C2-929.
33. Jacobs MR, Felmingham D, Appelbaum PC, Grüneberg RN; the Alexander Project Group. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003;52:229-46.
34. Weiss K, Restieri C, Jubinville N, Cayouette M, Dolce P, Eymard D, et al. Evolving Streptococcus pneumoniae resistance to antibiotics in the province of Quebec, Canada, from 2000 to 2004: a longitudinal survey [presentation at 44th Interscience Conference on Antimicrobial Agents and Chemotherapy]. 2004 Oct 30-Nov 4; Washington, DC. Abstr Intersci Conf Antimicrob Agents Chemother 2004:abstract no. C2-831.
35. Powis J, McGeer A, Green K, Vanderkooi O, Weiss K, Zhanel G, et al. In vitro antimicrobial susceptibilities of Streptococcus pneumoniae clinical isolates obtained in Canada in 2002. Antimicrob Agents Chemother 2004;48:3305-11.
36. Drummond M, Chancellor J, Duprat-Lomon I, Sagnier PP, Kuehne F, Barbieri M, et al. Moxifloxacin in hospital treatment of community-acquired pneumonia: a cost-effectiveness analysis across four European countries. Eur J Hosp Pharm 2004;2:67-75.
37. Santos PD, Hartmann AF, Irving SS, Merchant S, Meissner B, Farrelly EM, et al. The impact of implementing community-acquired pneumonia guidelines in a rural hospital. Pharm Ther 2004;29:42-7.
38. Palmer CS, Chunliu Z, Elixhauser A, Halpern MT, Rance L, Feagan BG, et al. Economic assessment of the community-acquired pneumonia intervention trial employing levofloxacin. Clin Ther 2000;22:250-64.
39. Halpern MT, Palmer CS, Zodet M, Kirsch JM. Cost-effectiveness of gemifloxacin versus clarithromycin to treat AECB: the GLOBE study. J Antimicrob Chemother 2001;47(Suppl 1):43.
40. Kirsch JM, Statham J, Bagchi I. Humanistic outcome benefits of gemifloxacin versus clarithromycin for the treatment of AECB: the Globe Study. J Antimicrob Chemother 2001;47(Suppl 1):44.
41. Wilson R, Ball P, Mandell L, File T, Kirsch J, Chinn C, et al; the GLOBE Study Group. Gemifloxacin long-term outcomes in bronchitis exacerbations (GLOBE) study - an assessment of health outcomes benefits in AECB patients following 5 days gemifloxacin therapy. J Antimicrob Chemother 2001;47(Suppl 1):44.
42. Eliopoulos GM. Quinolone resistance mechanisms in pneumococci. Clin Infect Dis 2004;38(Suppl 4):S350-6.
43. Pan XS, Ambler J, Mehtar S, Fisher LM. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob Agents Chemother 1996;40(10):2321-6.
44. Richardson DC, Bast D, McGeer A, Low DE. Evaluation of susceptibility testing to detect fluoroquinolone resistance mechanisms in Streptococcus pneumoniae. Antimicrob Agents Chemother 2001;45:1911-4.
45. Bast DJ, Low DE, Duncan CL, Kilburn L, Mandell LA, Davidson RJ, et al. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance. Antimicrob Agents Chemother 2000;44:3049-54.
46. Brueggemann AB, Coffman SL, Rhomberg P, Huynh H, Almer L, Nilius A, et al. Fluoroquinolone resistance in Streptococcus pneumoniae in the United States since 1994-1995. Antimicrob Agents Chemother 2002;46:680-8.
47. Gillespie SH, Voelker LL, Ambler JE, Traini C, Dickens A. Fluoroquinolone resistance in Streptococcus pneumoniae: evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutation. Microb Drug Res 2003;9:17-24.
48. Li X, Zhao X, Drlica K. Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin. Antimicrob Agents Chemother 2002;46:522-4.